Sumanta K. Pal, MD, on Renal Cancer Immunotherapy: Latest Developments

2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Tweet this page

Sumanta K. Pal, MD, of the City of Hope, discusses immunotherapy as a front-line treatment for kidney cancer and the strategy of VEGF blockade with immunotherapy, which is emerging as a possible treatment modality.

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.